Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

Abstract: A method for preparing high-purity granatin A: by means of a combination of low-temperature liquid phase chromatography and an isomerization conversion purification method, using pomegranate peel extract as a source material, granatin A of over 98% purity can be acquired, and can be used as a standard product for quality control of pomegranate peel, pomegranate flower, or other medicinal material with granatin A as the active ingredient.

Abstract: An isomerization feature-based method for purifying and preparing punicalagin is provided, wherein pomegranate peel extract is used as a raw material. The isomerization feature-based method avoids impurities contained in the punicalagin based on structural characteristics, for example, the punicalagin in the pomegranate peel extract has two mutually convertible isomers. In the isomerization feature-based method, a pilot-scale preparative liquid chromatography is used to obtain a large amount of the punicalagin having a purity higher than 98% from a complex pomegranate peel extract. The isomerization feature-based method is simple, an obtained punicalagin has high purities and a preparation is in a massive scale. The isomerization feature-based has a strong reference value for purification and preparation of compounds with isomerization features.

Abstract: Rupestonic acid derivatives are rupestonic acid derivative A- or B-type compounds, prepared through a condensation reaction from starting materials, i.e., a monomer compound of rupestonic acid and an aromatic amine or fatty amine or an organic alcohol, i.e., a fatty alcohol or an aromatic alcohol. Rupestonic acid, which is the monomer compound of sesquiterpene isolated from the plant Xinjiang Artemisia rupestric L., is used as a mother compound. Natural anti-virus lead compound with high activity are discovered by modifying the structure of the monomer compound of rupestonic acid. Activity results of the lead compound showed pharmaceutical application of anti-I, II flu virus and anti-I, II herpes simplex virus infection. These compounds can be used alone or in combination with one or more pharmaceutical acceptable, inert and nontoxic excipients or carries in a pharmaceutical composition.